TRILACICLIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where TRILACICLIB was used for Lung neoplasm malignant.
Most Reported Side Effects for TRILACICLIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 25 | 11.1% | 0 | 1 |
| Myelosuppression | 24 | 10.6% | 2 | 20 |
| Dyspnoea | 18 | 8.0% | 1 | 13 |
| Pneumonia | 18 | 8.0% | 4 | 17 |
| White blood cell count decreased | 18 | 8.0% | 1 | 14 |
| Platelet count decreased | 17 | 7.5% | 1 | 16 |
| Anaemia | 15 | 6.6% | 2 | 15 |
| Performance status decreased | 14 | 6.2% | 0 | 14 |
| Death | 13 | 5.8% | 13 | 1 |
| Infection | 12 | 5.3% | 0 | 11 |
| Haemorrhage | 11 | 4.9% | 0 | 11 |
| Red blood cell count decreased | 11 | 4.9% | 0 | 10 |
| Sepsis | 11 | 4.9% | 1 | 11 |
| Chest discomfort | 10 | 4.4% | 0 | 9 |
| Cough | 10 | 4.4% | 1 | 9 |
Other Indications for TRILACICLIB
Product used for unknown indication (92)
Myelosuppression (57)
Small cell lung cancer (20)
Small cell lung cancer extensive stage (13)
Bone marrow failure (7)
Infection prophylaxis (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)